ZA200800464B - Peptides for use in the treatment of obesity - Google Patents

Peptides for use in the treatment of obesity

Info

Publication number
ZA200800464B
ZA200800464B ZA200800464A ZA200800464A ZA200800464B ZA 200800464 B ZA200800464 B ZA 200800464B ZA 200800464 A ZA200800464 A ZA 200800464A ZA 200800464 A ZA200800464 A ZA 200800464A ZA 200800464 B ZA200800464 B ZA 200800464B
Authority
ZA
South Africa
Prior art keywords
obesity
peptides
treatment
Prior art date
Application number
ZA200800464A
Other languages
English (en)
Inventor
Sensfuss Ulrich
Christensen Leif
Spetzler Jane
Frieboes Kilian Waldemar Conde
Thoegersen Henning
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA200800464B publication Critical patent/ZA200800464B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200800464A 2005-07-18 2008-01-16 Peptides for use in the treatment of obesity ZA200800464B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05106554 2005-07-18

Publications (1)

Publication Number Publication Date
ZA200800464B true ZA200800464B (en) 2008-12-31

Family

ID=37527072

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800464A ZA200800464B (en) 2005-07-18 2008-01-16 Peptides for use in the treatment of obesity

Country Status (15)

Country Link
US (1) US20090203581A1 (pt)
EP (1) EP1907010A2 (pt)
JP (1) JP2009501755A (pt)
KR (1) KR20080031414A (pt)
CN (1) CN101222942A (pt)
AU (1) AU2006271792A1 (pt)
BR (1) BRPI0613984A2 (pt)
CA (1) CA2616583A1 (pt)
IL (1) IL188019A0 (pt)
MX (1) MX2007016024A (pt)
NO (1) NO20080745L (pt)
RU (1) RU2008100218A (pt)
TW (1) TW200744642A (pt)
WO (1) WO2007009894A2 (pt)
ZA (1) ZA200800464B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP2106407A2 (en) * 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN102027007A (zh) * 2008-05-16 2011-04-20 诺沃-诺迪斯克有限公司 长效的y2和/或y4受体激动剂
CN102131514B (zh) 2008-06-09 2014-08-20 帕拉丁科技公司 用于治疗性功能障碍的黑皮质素受体特异性肽
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
ES2561208T3 (es) 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
JP2012509862A (ja) * 2008-11-25 2012-04-26 ノヴォ・ノルディスク・アー／エス 肥満の治療のためのペプチド
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
CN102458436B (zh) 2009-06-08 2015-06-03 帕拉丁科技公司 黑皮质素受体特异性肽
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011033068A1 (en) * 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
EA021897B1 (ru) 2009-11-23 2015-09-30 Палатин Текнолоджиз, Инк. Циклические пептиды, специфичные к рецептору меланокортина-1
MX2012005859A (es) 2009-11-23 2012-12-17 Palatin Technologies Inc Peptidos lineales especificos del receptor de melanocortina-1.
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
CN103379919A (zh) 2011-01-26 2013-10-30 诺沃—诺迪斯克有限公司 瘦蛋白衍生物
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
JP6352806B2 (ja) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
RU2641198C3 (ru) 2012-03-22 2021-12-10 Ново Нордиск А/С Композиции glp-1 пептидов и их получение
EP2829301A1 (en) 2013-07-25 2015-01-28 Bruno Escarguel Medical device for radiotherapy treatment
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
US9085637B2 (en) 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
WO2016198682A1 (en) 2015-06-12 2016-12-15 Novo Nordisk A/S Selective pyy compounds and uses thereof
US11725035B2 (en) 2016-08-09 2023-08-15 Stipe Therapeutics Aps Methods of treating a disorder associated with with insufficient stimulator of interferon genes (STING) activity
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
CN112557497B (zh) * 2020-11-30 2022-11-11 中国药科大学 肼苯哒嗪在基质辅助激光解吸电离质谱中用作基质的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457864A (en) * 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US5049547A (en) * 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
NZ228855A (en) * 1988-04-25 1992-08-26 Hoffmann La Roche Tyrosine analogues and peptides containing them especially cholecystokinin (cck) analogues
US5128448A (en) * 1990-01-10 1992-07-07 Hoffman-La Roche Inc. CCK analogs with appetite regulating activity
JP3734828B2 (ja) * 1993-05-05 2006-01-11 ローズ，キース ポリオキシム化合物及びそれらの調整
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
AU2002322466B2 (en) * 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
CA2523408A1 (en) * 2003-05-09 2004-11-18 Novo Nordisk A\S Peptides for use in treating obesity

Also Published As

Publication number Publication date
RU2008100218A (ru) 2009-08-27
WO2007009894A3 (en) 2007-09-13
US20090203581A1 (en) 2009-08-13
CA2616583A1 (en) 2007-01-25
TW200744642A (en) 2007-12-16
JP2009501755A (ja) 2009-01-22
NO20080745L (no) 2008-04-09
EP1907010A2 (en) 2008-04-09
WO2007009894A2 (en) 2007-01-25
MX2007016024A (es) 2008-03-10
CN101222942A (zh) 2008-07-16
KR20080031414A (ko) 2008-04-08
BRPI0613984A2 (pt) 2011-03-01
AU2006271792A1 (en) 2007-01-25
IL188019A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
ZA200800464B (en) Peptides for use in the treatment of obesity
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
GB2429013C (en) Peptides for treatment and diagnosis of autoimmunedisease
EP1957462A4 (en) NEW 2-AMINO-HETEROCYCLES USEFUL FOR THE TREATMENT OF ABETA-RELATED DISEASES
PT3424932T (pt) Boronoftalidas para utilização terapêutica
PT2450041T (pt) Gel de testosterona melhorado e método para a sua utilização
PL1685834T3 (pl) Zastosowanie kwasu pinolenowego do leczenia otyłości
EP1976864A4 (en) NEW PEPTIDE AND ITS USE
GB2432410B (en) Material treatment unit
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
IL185308A0 (en) Replikin peptides and uses thereof
PT1945243E (pt) Utilização da calcitonina para o tratamento da ar
GB0609121D0 (en) Peptide Therapy
GB0511769D0 (en) Treatment
GB0526120D0 (en) Therapeutic peptides
GB0501655D0 (en) Therapeutic use
IL188310A0 (en) Thrombospondin-1 derived peptides and treatment methods
IL185575A0 (en) Benzoxazocines and their therapeutic use
GB0413635D0 (en) Ultrasonic treatment
GB0526292D0 (en) A composition for use in the treatment of a surface
GB0403467D0 (en) Body warming apparatus
GB0803201D0 (en) Two-part dressing suitable for use in surgery
HK1125634A1 (en) Pharmaceutical for use in the treatment of ureterolithiasis
GB0503093D0 (en) Ricin-binding peptide and methods for use thereof
GB0501657D0 (en) Therapeutic use